XBiotech Inc XBIT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.33
- Day Range
- $2.33–2.38
- 52-Week Range
- $2.09–3.61
- Bid/Ask
- $2.34 / $2.35
- Shares Outstanding
- 30.49M
- Market Cap
- $71.34M
- Volume/Avg
- 20,154 / 33,397
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 87
- Website
- http://www.xbiotech.com
Valuation
|
Metric
|
XBIT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.53 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
XBIT
Financial Strength
|
Metric
|
XBIT
|
|---|---|
Quick Ratio | 38.60 |
Current Ratio | 39.03 |
Interest Coverage | — |
Quick Ratio
XBIT
Profitability
|
Metric
|
XBIT
|
|---|---|
Return on Assets (Normalized) | −25.15% |
Return on Equity (Normalized) | −26.19% |
Return on Invested Capital (Normalized) | −28.93% |
Return on Assets
XBIT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Qkfljgw | Wnxdy | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vnncrpbz | Hhyycm | $64B | |||
| argenx SE ADR
ARGX
| Sjxnjpgsz | Czmx | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Sfzpszffx | Njrxg | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Pptggwdgdl | Czgwlj | $24B | |||
| BioNTech SE ADR
BNTX
| Scsdtpl | Jtnsc | $23B | |||
| Incyte Corp
INCY
| Ykybcwjv | Mfcsb | $22B | |||
| Moderna Inc
MRNA
| Vtpywdkx | Dfsj | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Tvqtjzdh | Xyxdm | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Rmkglzbf | Tybs | $13B |
United States